A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
Latest Information Update: 26 Apr 2024
At a glance
- Drugs Alectinib (Primary) ; Cobimetinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 22 Apr 2024 Planned End Date changed from 30 Nov 2024 to 1 Jan 2027.
- 22 Apr 2024 Planned primary completion date changed from 30 Nov 2022 to 1 Jan 2025.
- 22 Apr 2024 Status changed from recruiting to active, no longer recruiting.